Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis Bioequivalence Study in Healthy Adults
NCT07587697Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started May 2026; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT07587697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587697.